Drug intelligence / Profile preview

LX-96

Development stage: Preclinical
Lead developer: Paradox Immunotherapeutics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

LX-96 is a monoclonal antibody under development by Paradox Immunotherapeutics for the treatment of late-stage immunoglobulin light chain amyloidosis. It acts as an inhibitor of immunoglobulin G (IgG), targeting pathological processes associated with amyloid deposition in this disease. The drug is currently in preclinical development and has not yet entered clinical trials or received regulatory approval[1][2][3].

Other names: LX 96LX96LX-96

Beyond the preview

Go deeper on LX-96.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LX-96.

Explore the full profile